Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment

NCT01378143 is registered in ClinicalTrials.gov with Oncozyme Pharma Inc. as lead sponsor.

NCT NCT01378143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01378143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment
Lead sponsor
Oncozyme Pharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
July 31, 2014
Enrollment
53 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer